Structured infection prevention and treatment cuts maternal deaths and severe complications by nearly one-third, a trial in 59 hospitals has found.

The APT-Sepsis intervention, tested on more than 430,000 women in Malawi and Uganda, showed that systematic improvements in hygiene, infection management and sepsis care reduced maternal mortality in low-resource settings.

Maternal sepsis, a life-threatening response to infection that causes organ dysfunction, kills one mother every 30 minutes globally.

The burden falls heaviest on women in low and middle-income countries where healthcare resources are limited.

The Active Prevention and Treatment of Maternal Sepsis programme, developed by researchers at the University of Liverpool, the World Health Organization and the UN’s Special Programme in Human Reproduction, focused on three key areas: improving hand hygiene compliance, strengthening infection prevention practices, and implementing the FAST-M sepsis bundle for rapid treatment.

The FAST-M bundle provides a structured approach to sepsis care: fluids for resuscitation, antibiotics to fight infection, source control to address the infection’s origin, transfer to appropriate facilities when needed, and continuous monitoring of the patient’s condition.

Results showed the intervention’s effectiveness increased over time, achieving a 47 per cent reduction in infection-related deaths and complications by the final month of the trial.#

The programme proved equally effective in both participating countries and required no costly additional resources beyond training and protocol implementation.

David Lissauer is NIHR professor of global maternal and foetal health at the University of Liverpool.

The researcher said: “These results are hugely significant.

“For too long, maternal sepsis has been a leading but neglected cause of preventable maternal deaths worldwide.

“Our findings demonstrate that APT-Sepsis provides a practical, sustainable, and effective solution.

“With a 32 per cent reduction in infection-related maternal deaths and life-threatening complications, this programme has the potential to transform care.

“Policymakers now have compelling evidence to scale up these interventions so that fewer women die from preventable infections during pregnancy and childbirth.

The programme achieved its results by supporting healthcare workers to adopt evidence-based practices within existing health systems.

Staff received training on hand hygiene standards, infection prevention protocols, and early sepsis detection methods.

Jeremy Farrar, assistant director-general at WHO, emphasised the broader implications: “The APT-Sepsis programme is a testament to what can be achieved when science, policy and frontline care come together.

“Reducing maternal infections and deaths by over 30 per cent is not just a clinical success – it’s a call to action for global health systems to prioritise infection prevention in maternal care.

“We must ensure these life-saving practices are scaled and sustained across all settings.”

Research suggests Jinfeng Pills may restore a thin endometrium, a cause of infertility in up to 2.5 per cent of women.

The study found that Jinfeng Pills, a traditional Chinese herbal formula used historically in the Chinese imperial harem, increased endometrial thickness in female rats.

The treatment improved glandular and vascular density and boosted molecular markers that support a receptive uterine environment.

Thin endometrium, defined as a uterine lining under 7 mm, can follow repeated uterine procedures, infections or hormonal disruption.

These can limit blood flow and proper growth of the lining, making embryo implantation difficult. Current treatments remain limited.

Researchers created a thin endometrium model in Sprague-Dawley rats using 95 per cent ethanol to cause a controlled chemical injury to the uterine lining.

Animals were assigned to four groups: a control group, an untreated model group, a group receiving estradiol valerate (a standard hormonal therapy) and a group treated with Jinfeng Pills.

The team used histological staining (tissue examination with dyes), ELISA (a protein test), immunofluorescence (light-tagged antibody detection) and qPCR (a gene expression assay) to assess endometrial structure, serum biomarkers and gene and protein activity linked to implantation.

Rats given Jinfeng Pills developed a thicker, undulating endometrium with higher gland density and enhanced vascularisation.

Serum levels of vascular endothelial growth factor (VEGF), a protein that stimulates new blood vessel growth, were notably higher.

The formula contains herbs and animal-derived ingredients traditionally linked to reproductive health, including Epimedium, Citronella, Motherwort, Cinnamon, Ass Hide Glue, Velvet Antler, Ginseng, Privet Fruit and Polygonum multiflorum.

According to traditional Chinese medicine principles, Jinfeng Pills work by “warming the kidney, tonifying Yang, nourishing the liver and spleen, regulating Chong and Ren vessels, and promoting blood circulation.”

The study offers molecular evidence consistent with these claims by showing enhanced vascular regeneration and support for endometrial repair.

The authors noted: “This study experimentally confirms the efficacy of Jinfeng Pills in treating thin endometrium in a rat model and to preliminarily clarify its mechanism of action.”

The findings point to a potential role alongside modern reproductive medicine.

Human trials are needed to show whether these results translate into clinical benefits for women with thin endometrium who are seeking pregnancy.

Roche’s experimental oral drug giredestrant improved disease-free survival after breast cancer surgery in an interim late-stage trial, the company said.

A scheduled interim analysis found the pill delivered a clinically meaningful improvement in keeping patients disease-free after surgery, outperforming standard endocrine therapy. Disease-free survival means the cancer has not returned after treatment.

Roche announced the results on Tuesday and said further details will be shared at a forthcoming medical conference as it moves towards regulatory approval.

The prospect of curbing the spread of early-stage disease to other parts of the body lifted Roche’s shares by 6.1 per cent to 304.90 Swiss francs at 9.39am GMT.

JPMorgan analysts called the update a “significant positive surprise” and estimated that, if approved, this use could generate about US$5bn a year.

Some investors have worried Roche leans too heavily on older blockbusters, even as the family-controlled group pushes into the fast-growing obesity market and seeks to diversify beyond oncology.

Giredestrant is an oral selective oestrogen receptor degrader (SERD), a class designed to break down the oestrogen receptor and inhibit tumours that grow in response to the hormone. Such cancers are estimated to make up as much as 80 per cent of breast cancer cases.

Rivals are also targeting this space. AstraZeneca is developing camizestrant, while Sanofi’s efforts in oral SERDs have failed.